Manufacturer of Controlled Substances; Notice of Application, 75497-75498 [2010-30360]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 232 / Friday, December 3, 2010 / Notices
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C 958(a); 21 USC 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
DATED: November 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–30338 Filed 12–2–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated March 29, 2010, and
published in the Federal Register on
April 16, 2010, 75 FR 20000, Lipomed,
Inc., One Broadway, Cambridge,
Massachusetts 02142, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances:
mstockstill on DSKH9S0YB1PROD with NOTICES
Drug
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ..................
N–Ethylamphetamine (1475) ........
Fenethylline (1503) .......................
Methaqualone (2565) ...................
Gamma
Hydroxybutyric
Acid
(2010).
Lysergic acid diethylamide (7315)
2,5–Dimethoxy-4-(n)propylthiophenethylamine
(7348).
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
3,4,5–Trimethoxyamphetamine
(7390).
4–Bromo-2,5dimethoxyamphetamine (7391).
4–Bromo-2,5dimethoxyphenethylamine
(7392).
4–Methyl-2,5dimethoxyamphetamine (7395).
2,5–Dimethoxyamphetamine
(7396).
2,5–Dimethoxy-4ethylamphetamine (7399).
3,4–Methylenedioxyamphetamine
(7400).
3,4–Methylenedioxy-Nethylamphetamine (7404).
VerDate Mar<15>2010
16:09 Dec 02, 2010
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Jkt 223001
Schedule
Drug
3,4–
Methylenedioxymethamphetamine (7405).
4–Methoxyamphetamine (7411) ...
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
N–Benzylpiperazine (7493) ..........
Acetyldihydrocodeine (9051) ........
Dihydromorphine (9145) ...............
Heroin (9200) ...............................
Normorphine (9313) .....................
Pholcodine (9314) ........................
Tilidine (9750) ...............................
3–Methylfentanyl (9813) ...............
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Alfentanil (9737) ...........................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
the basic classes of controlled
substances listed.
I
Dated: November 18, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import
analytical reference standards for
distribution to its customers for research
and analytical purposes.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Lipomed, Inc. to import the basic
classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Lipomed, Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
PO 00000
Frm 00047
Fmt 4703
75497
Sfmt 4703
[FR Doc. 2010–30334 Filed 12–2–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on October 29, 2010,
Siegfried (USA), Inc., 33 Industrial Park
Road, Pennsville, New Jersey 08070,
made application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Hydromorphinol (9301), a basic class of
controlled substance listed in schedule
I.
The company plans to manufacture
small quantities of the listed controlled
substance in bulk for distribution to its
customers for use as reference
standards.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than February 1, 2011.
Dated: November 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–30351 Filed 12–2–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to 1301.33(a), Title 21 of the
Code of Federal Regulations (CFR), this
is notice that on September 13, 2010,
Chattem Chemicals, Inc., 3801 St. Elmo
Avenue, Building 18, Chattanooga,
Tennessee 37409, made application by
E:\FR\FM\03DEN1.SGM
03DEN1
75498
Federal Register / Vol. 75, No. 232 / Friday, December 3, 2010 / Notices
letter to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of 4-Anilino-NPhenethyl-4-Piperidine (ANPP) (8333), a
basic class of controlled substance listed
in schedule II.
The company plans to use this
controlled substance in the manufacture
of another controlled substance.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than February 1, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
eventually cease and Agilent
Technologies will take over all of Varian
Inc.’s activities with regard to controlled
substances, requiring possession of a
DEA registration as a bulk manufacturer
issued to Agilent Technologies.
Presently, Agilent Technologies’
activities with regard to controlled
substances will be exactly the same as
performed by Varian, Inc.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR § 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than February 1, 2011.
Dated: November 18, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–30360 Filed 12–2–10; 8:45 am]
BILLING CODE 4410–09–P
the public interest at this time. DEA has
investigated Boehringer Ingelheim
Chemicals, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–30352 Filed 12–2–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Mine Safety and Health Administration
[FR Doc. 2010–30358 Filed 12–2–10; 8:45 am]
BILLING CODE 4410–09–P
Petitions for Modification of Existing
Mandatory Safety Standards
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
AGENCY:
Manufacturer of Controlled
Substances; Notice of Application
Drug Enforcement Administration
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 8, 2010,
Agilent Technologies, 25200
Commercentre Drive, Lake Forest,
California 92630–8810, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule II:
Manufacturer of Controlled
Substances; Notice of Registration
DEPARTMENT OF JUSTICE
Drug
Schedule
mstockstill on DSKH9S0YB1PROD with NOTICES
Phencyclidine (7471) ....................
1-piperidinocyclohex- ....................
anecarbonitrile (8603) ..................
Benzoylecgonine (9180) ...............
Drug
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances for use in diagnostic
products.
Agilent Technologies submitted this
application because, effective May 14,
2010, Varian, Inc., located at 25200
Commercentre Drive, Lake Forest,
California 92630–8810, became a
wholly-owned subsidiary of Agilent
Technologies. Varian, Inc.’s legal
existence as a corporation and as a DEA
registrant as a bulk manufacturer will
VerDate Mar<15>2010
16:09 Dec 02, 2010
Jkt 223001
By Notice dated May 28, 2010 and
published in the Federal Register on
June 8, 2010, (75 FR 32506), Boehringer
Ingelheim Chemicals, Inc., 2820 N.
Normandy Drive, Petersburg, Virginia
23805–9372, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances:
Schedule
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers for formulation
into finished pharmaceuticals.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Boehringer Ingelheim Chemicals, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
Mine Safety and Health
Administration (MSHA), Labor.
ACTION: Notice.
Section 101(c) of the Federal
Mine Safety and Health Act of 1977 and
30 CFR part 44 govern the application,
processing, and disposition of petitions
for modification. This notice is a
summary of petitions for modification
filed by the parties listed below to
modify the application of existing
mandatory safety standards published
in Title 30 of the Code of Federal
Regulations.
SUMMARY:
All comments on the petitions
must be received by the Office of
Standards, Regulations and Variances
on or before January 3, 2011.
ADDRESSES: You may submit your
comments, identified by ‘‘docket
number’’ on the subject line, by any of
the following methods:
1. Electronic Mail: zzMSHAcomments@dol.gov. Include the docket
number of the petition in the subject
line of the message.
2. Facsimile: 1–202–693–9441.
3. Regular Mail: MSHA, Office of
Standards, Regulations and Variances,
1100 Wilson Boulevard, Room 2350,
Arlington, Virginia 22209–3939,
Attention: Patricia W. Silvey, Director,
Office of Standards, Regulations and
Variances.
DATES:
E:\FR\FM\03DEN1.SGM
03DEN1
]]>Agencies
[Federal Register Volume 75, Number 232 (Friday, December 3, 2010)]
[Notices]
[Pages 75497-75498]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-30360]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to 1301.33(a), Title 21 of the Code of Federal Regulations
(CFR), this is notice that on September 13, 2010, Chattem Chemicals,
Inc., 3801 St. Elmo Avenue, Building 18, Chattanooga, Tennessee 37409,
made application by
[[Page 75498]]
letter to the Drug Enforcement Administration (DEA) to be registered as
a bulk manufacturer of 4-Anilino-N-Phenethyl-4-Piperidine (ANPP)
(8333), a basic class of controlled substance listed in schedule II.
The company plans to use this controlled substance in the
manufacture of another controlled substance.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substance, may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than February 1, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-30360 Filed 12-2-10; 8:45 am]
BILLING CODE 4410-09-P
